Dilon Acquires Navigator Gamma Probe Company
By HospiMedica International staff writers Posted on 13 Jan 2014 |
Dilon Technologies, Inc. (Newport News, VA, USA) has acquired the assets of the Navigator gamma probe business from RMD Instruments Corp. (Watertown, MA, USA), a subsidiary of Dynasil Corporation of America.
RMD Instruments manufactures and sells a range of intraoperative surgical probes that are distributed both in the United States and worldwide. The acquired products are used in surgery for procedures such as pulmonary wedge resection and sentinel lymph node biopsy. The company recently introduced its Navigator 2.0 wireless probe, which has been very well received by the market place.
“In addition to our market leadership in the small field-of-view molecular breast imaging market, this acquisition is consistent with our objective of expanding our product offering in both the diagnostic and surgical segments of the market and comes on the heels of our recent agreement with Digirad [Suwanee, GA, USA],” commented Robert G. Moussa, Dilon’s CEO.
“We are pleased to have found a wonderful home for our Navigator Probe technology, one of the most widely used gamma probes for cancer surgery in the marketplace. Dilon Technologies is well situated to expand the gamma probe market and we look forward to working with them over the coming months to transition the product from our manufacturing facility to Dilon,” commented Peter Sulick, Dynasil’s chairman and interim CEO.
Dynasil, for the time being, will continue to manufacture and distribute the products, maintaining continuity in supply and regulatory compliance.
Dilon Technologies’ keystone product, the Dilon molecular imaging system (MBI), is a high-resolution, small field-of-view digital gamma camera, optimized for MBI/breast-specific gamma imaging (BSGI). MBI utilizes radiotracer uptake to detect the increased metabolic activity of breast lesions and therefore, is not affected by breast density. Both the Dilon 6800 and Acella systems provide high photon sensitivity; and Dilon’s GammaLoc system is the only localization device on the market to enable molecular-guided breast biopsy.
Digirad is one of the largest US providers of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers, and also sells medical diagnostic imaging systems for nuclear cardiology and general nuclear medicine applications.
Related Links:
Dilon Technologies
RMD Instruments
Digirad
RMD Instruments manufactures and sells a range of intraoperative surgical probes that are distributed both in the United States and worldwide. The acquired products are used in surgery for procedures such as pulmonary wedge resection and sentinel lymph node biopsy. The company recently introduced its Navigator 2.0 wireless probe, which has been very well received by the market place.
“In addition to our market leadership in the small field-of-view molecular breast imaging market, this acquisition is consistent with our objective of expanding our product offering in both the diagnostic and surgical segments of the market and comes on the heels of our recent agreement with Digirad [Suwanee, GA, USA],” commented Robert G. Moussa, Dilon’s CEO.
“We are pleased to have found a wonderful home for our Navigator Probe technology, one of the most widely used gamma probes for cancer surgery in the marketplace. Dilon Technologies is well situated to expand the gamma probe market and we look forward to working with them over the coming months to transition the product from our manufacturing facility to Dilon,” commented Peter Sulick, Dynasil’s chairman and interim CEO.
Dynasil, for the time being, will continue to manufacture and distribute the products, maintaining continuity in supply and regulatory compliance.
Dilon Technologies’ keystone product, the Dilon molecular imaging system (MBI), is a high-resolution, small field-of-view digital gamma camera, optimized for MBI/breast-specific gamma imaging (BSGI). MBI utilizes radiotracer uptake to detect the increased metabolic activity of breast lesions and therefore, is not affected by breast density. Both the Dilon 6800 and Acella systems provide high photon sensitivity; and Dilon’s GammaLoc system is the only localization device on the market to enable molecular-guided breast biopsy.
Digirad is one of the largest US providers of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers, and also sells medical diagnostic imaging systems for nuclear cardiology and general nuclear medicine applications.
Related Links:
Dilon Technologies
RMD Instruments
Digirad
Latest Business News
- Johnson & Johnson Acquires Cardiovascular Medical Device Company Shockwave Medical
- Mindray to Acquire Chinese Medical Device Company APT Medical
- Olympus Acquires Korean GI Stent Maker Taewoong Medical
- Karl Storz Acquires British AI Specialist Innersight Labs
- Stryker to Acquire French Joint Replacement Company SERF SAS
- Medical Illumination Acquires Surgical Lighting Specialist Isolux
- 5G Remote-Controlled Robots to Enable Even Cross-Border Surgeries
- International Hospital Federation Announces 2023 IHF Award Winners
- Unprecedented AI Integration Transforming Surgery Landscape, Say Experts
- New WHO Guidelines to Revolutionize AI in Healthcare
- Getinge Acquires US-Based Medical Equipment Provider Healthmark Industries
- Global Surgical Lights Market Driven by Increasing Number of Procedures
- Global Capsule Endoscopy Market Driven by Demand for Accurate Diagnosis of Gastrointestinal Conditions
- Global OR Integration Market Driven by Need for Improved Workflow Efficiency and Productivity
- Global Endoscopy Devices Market Driven by Increasing Adoption of Endoscopes in Surgical Procedures
- Global Minimally Invasive Medical Devices Market Driven by Benefits of MIS Procedures